LENZ Therapeutics, Inc. (LENZ)
3.20
-0.30
(-8.57%)
USD |
NASDAQ |
Nov 18, 16:00
3.21
+0.01
(+0.31%)
After-Hours: 20:00
LENZ Therapeutics Total Liabilities (Quarterly) : 17.75M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 17.75M |
| June 30, 2026 | 17.33M |
| March 31, 2026 | 26.04M |
| December 31, 2025 | 21.54M |
| September 30, 2025 | 16.78M |
| June 30, 2025 | 10.97M |
| March 31, 2025 | 9.242M |
| December 31, 2024 | 11.22M |
| September 30, 2024 | 8.727M |
| June 30, 2024 | 9.718M |
| March 31, 2024 | 19.16M |
| December 31, 2023 | 19.70M |
| Date | Value |
|---|---|
| September 30, 2023 | 62.21M |
| June 30, 2023 | 62.90M |
| March 31, 2023 | 33.77M |
| December 31, 2022 | 25.61M |
| September 30, 2022 | 18.39M |
| June 30, 2022 | 15.33M |
| March 31, 2022 | 17.31M |
| December 31, 2021 | 12.14M |
| September 30, 2021 | 16.02M |
| June 30, 2021 | 7.922M |
| March 31, 2021 | 6.457M |
| December 31, 2020 | 32.36M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| EyePoint, Inc. | 57.63M |
| Ligand Pharmaceuticals, Inc. | 1.276B |
| Bristol Myers Squibb Co. | 65.37B |
| Context Therapeutics, Inc. | 5.533M |
| Neumora Therapeutics, Inc. | 76.50M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 209.75M |
| Shareholders Equity (Quarterly) | 192.00M |
| Debt to Equity Ratio | 0.0024 |
| Current Ratio | 11.66 |
| Net Debt Paydown Yield | 0.10% |